Latest Insider Transactions at Bluebird Bio, Inc. (BLUE)
This section provides a real-time view of insider transactions for Bluebird Bio, Inc. (BLUE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of bluebird bio, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of bluebird bio, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 11
2021
|
Jason Cole Chief Strategy & Financial Off |
BUY
Other acquisition or disposition
|
Direct |
168,427
+20.43%
|
-
|
|
Nov 11
2021
|
Philip D Gregory Chief Scientific Officer |
BUY
Other acquisition or disposition
|
Direct |
12,799
+6.17%
|
-
|
|
Nov 11
2021
|
William R. Sellers Director |
BUY
Other acquisition or disposition
|
Direct |
657
+7.71%
|
-
|
|
Nov 11
2021
|
Mark Vachon |
BUY
Other acquisition or disposition
|
Direct |
6,241
+38.67%
|
-
|
|
Nov 11
2021
|
John O Agwunobi |
BUY
Other acquisition or disposition
|
Direct |
6,241
+33.19%
|
-
|
|
Nov 11
2021
|
Elisabeth Leiderman |
BUY
Other acquisition or disposition
|
Direct |
9,361
+50.0%
|
-
|
|
Nov 11
2021
|
Najoh Tita Reid |
BUY
Other acquisition or disposition
|
Direct |
9,361
+50.0%
|
-
|
|
Nov 11
2021
|
Gina Consylman Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
100,385
+50.0%
|
-
|
|
Nov 11
2021
|
Jessica Whitten Chief Accounting Officer |
BUY
Other acquisition or disposition
|
Direct |
42,405
+40.97%
|
-
|
|
Nov 11
2021
|
Thomas J Klima |
BUY
Other acquisition or disposition
|
Direct |
50,192
+50.0%
|
-
|
|
Oct 15
2021
|
Elisabeth Leiderman |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+50.0%
|
-
|
|
Sep 29
2021
|
Najoh Tita Reid |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+50.0%
|
-
|
|
Sep 29
2021
|
Sarah Js Glickman Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+50.0%
|
-
|
|
Sep 07
2021
|
Marcela V. Maus Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+50.0%
|
-
|
|
Aug 02
2021
|
Andrew Obenshain President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+41.74%
|
-
|
|
Aug 02
2021
|
Jason Cole Chief Strategy & Financial Off |
BUY
Grant, award, or other acquisition
|
Direct |
64,531
+25.49%
|
-
|
|
Aug 02
2021
|
Nick Leschly |
BUY
Grant, award, or other acquisition
|
Direct |
102,607
+11.84%
|
-
|
|
Aug 02
2021
|
William D Baird Iii Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
67,169
+28.67%
|
-
|
|
Aug 02
2021
|
Philip D Gregory Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
67,853
+26.21%
|
-
|
|
Jun 15
2021
|
Daniel Lynch Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,353
+26.12%
|
-
|
|
Jun 15
2021
|
John O Agwunobi |
BUY
Grant, award, or other acquisition
|
Direct |
3,109
+24.79%
|
-
|
|
Jun 15
2021
|
Wendy L Dixon Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,109
+26.19%
|
-
|
|
Jun 15
2021
|
Ramy Ibrahim Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,109
+36.71%
|
-
|
|
Jun 15
2021
|
William R. Sellers Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,109
+31.63%
|
-
|
|
Jun 15
2021
|
Mark Vachon |
BUY
Grant, award, or other acquisition
|
Direct |
3,109
+31.48%
|
-
|
|
Jun 15
2021
|
Denice Torres Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,109
+34.67%
|
-
|
|
Jun 04
2021
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
511
-1.27%
|
$15,330
$30.75 P/Share
|
|
Jun 01
2021
|
Thomas J Klima |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+50.0%
|
$775,000
$31.11 P/Share
|
|
May 12
2021
|
Nick Leschly |
BUY
Bona fide gift
|
Indirect |
123,000
+50.0%
|
-
|
|
May 12
2021
|
Nick Leschly |
SELL
Bona fide gift
|
Indirect |
123,000
-72.91%
|
-
|
|
May 03
2021
|
Jason Cole Chief Strategy & Financial Off |
SELL
Open market or private sale
|
Direct |
38
-0.08%
|
$1,140
$30.15 P/Share
|
|
May 03
2021
|
Nick Leschly |
SELL
Open market or private sale
|
Direct |
444
-0.14%
|
$13,320
$30.15 P/Share
|
|
May 03
2021
|
Philip D Gregory Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
39
-0.08%
|
$1,170
$30.15 P/Share
|
|
May 03
2021
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
29
-0.07%
|
$870
$30.15 P/Share
|
|
Apr 05
2021
|
David Davidson Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
42
-0.09%
|
$1,260
$30.21 P/Share
|
|
Apr 05
2021
|
Jason Cole Chief Strategy & Financial Off |
SELL
Open market or private sale
|
Direct |
37
-0.08%
|
$1,110
$30.21 P/Share
|
|
Apr 05
2021
|
Philip D Gregory Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
39
-0.08%
|
$1,170
$30.21 P/Share
|
|
Apr 05
2021
|
Nick Leschly |
SELL
Open market or private sale
|
Direct |
444
-0.14%
|
$13,320
$30.21 P/Share
|
|
Apr 05
2021
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
29
-0.07%
|
$870
$30.21 P/Share
|
|
Mar 04
2021
|
Nick Leschly |
BUY
Exercise of conversion of derivative security
|
Direct |
203,355
+39.8%
|
$1,016,775
$5.5 P/Share
|
|
Mar 02
2021
|
Philip D Gregory Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
39
-0.08%
|
$1,131
$29.58 P/Share
|
|
Mar 02
2021
|
Jason Cole Chief Strategy & Financial Off |
SELL
Open market or private sale
|
Direct |
38
-0.08%
|
$1,102
$29.58 P/Share
|
|
Mar 02
2021
|
David Davidson Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
42
-0.09%
|
$1,218
$29.58 P/Share
|
|
Mar 02
2021
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
34
-0.08%
|
$986
$29.58 P/Share
|
|
Mar 02
2021
|
Nick Leschly |
SELL
Open market or private sale
|
Direct |
444
-0.42%
|
$12,876
$29.58 P/Share
|
|
Feb 17
2021
|
Jason Cole Chief Strategy & Financial Off |
SELL
Open market or private sale
|
Direct |
665
-1.37%
|
$18,620
$28.16 P/Share
|
|
Feb 17
2021
|
David Davidson Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
698
-1.44%
|
$19,544
$28.16 P/Share
|
|
Feb 17
2021
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
749
-1.83%
|
$20,972
$28.16 P/Share
|
|
Feb 17
2021
|
Philip D Gregory Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
664
-1.39%
|
$18,592
$28.16 P/Share
|
|
Feb 17
2021
|
Katy Burnett Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
518
-11.22%
|
$14,504
$28.16 P/Share
|